Epigenetic enzyme found to be lacking in some patients with Crohn’s disease – Medical Xpress

March 3, 2017 High magnification micrograph of Crohn's disease. Biopsy of esophagus. H&E stain. Credit: Nephron/Wikipedia

A Massachusetts General Hospital (MGH) research team has found how a variant in an important epigenetic enzymepreviously associated by population-based genetic studies with Crohn's disease and other immune disordersinterferes with the action of the innate immune system, potentially upsetting the healthy balance between the microbial population of the gastrointestinal tract and the immune response. In their paper published in Science Immunology the team reports findings that SP140an epigenetic reader protein that plays a critical role in determining whether or not target genes are expressedis essential to suppressing inappropriate gene expression in macrophages, innate immune cells that are critical to maintaining intestinal balance.

"More than 400 enzymes write, read or erase the epigenome, and mutations in these enzymes are some of the most prevalent perturbations in cancers, prompting rigorous efforts to identify compounds that could inhibit their function and reset gene expression," says Kate Jeffrey, PhD of the MGH Gastrointestinal Unit and the Center for the Study of Inflammatory Bowel Disease, corresponding author of the Science Immunology report. "Our knowledge of epigenomic enzyme mutations in immune-mediated disease is lagging well behind the cancer field, and our studythe first to examine the function of SP140 in any detailshows how its loss in Crohn's disease triggers intestinal inflammation."

SP140 is predominantly expressed in immune cells, and a variant form of the gene has been associated with Crohn's disease, multiple sclerosis and chronic lymphocytic leukemia. Prior to this study both the normal function of the SP140 protein and how the gene variant affected the protein and caused disease were unknown. In a series of experiments, Jeffrey's team showed that the unaltered form of SP140 is required to maintain the appropriate expression of genes that define the identity and function of macrophages. The immune disorder variantcharacterized by 17 individual sequence changes - resulted in a loss of SP140 protein that compromised the ability of macrophages to respond to microbial signals.

The researchers also showed that reducing SP140 expression in the immune cells of a mouse model of colitis increased intestinal inflammation. In addition, examining intestinal biopsy samples from a group of Crohn's disease patients revealed that those in whom SP140 expression was reduced responded better to anti-TNF (tumor necrosis factor) therapya treatment for inflammatory conditions that is effective in only about half of Crohn's patients - than did patients with typical SP140 levels.

"Finding this correlation between lower intestinal levels of SP140 and a better response to anti-TNF represents a potential precision medicine strategy for tailoring anti-TNF-like therapies to Crohn's patients carrying the variant form of SP140," says Jeffrey, who is an assistant professor of Medicine at Harvard Medical School. "Our study may also lead to better inflammatory bowel disease therapies by highlighting the critical role of epigenetic mechanisms for intestinal health. Although directly targeting SP140 would not be a good option, since its loss is detrimental to intestinal health, leveraging other epigenetic enzyme inhibitors that promote protective innate immune responses in the intestine could be a real therapeutic option"

Additional research is needed to better understand exactly how SP140 normally limits the expression of inappropriate genes and whether this function is limited to macrophages or also occurs in other SP140-expressing immune cells, Jeffrey notes. Her team also hopes to investigate the role of the Crohn's-associated SP140 variant in multiple sclerosis and chronic lymphocytic leukemia, along with identifying other epigenetic enzymes that may be therapeutically targetable in inflammatory bowel disease and other immune-driven disorders.

Explore further: Crohn's disease risk and prognosis determined by different genes, study finds

More information: "Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140," Science Immunology, immunology.sciencemag.org/lookup/doi/10.1126/sciimmunol.aag3160

A Massachusetts General Hospital (MGH) research team has found how a variant in an important epigenetic enzymepreviously associated by population-based genetic studies with Crohn's disease and other immune disordersinterferes ...

Scientists have revealed for the first time how immature mouse immune cells, called T cells, choose which type of skills they will develop to fight malaria infection. Reported today in Science Immunology, researchers from ...

(HealthDay)An experimental drug may significantly reduce the itching and improve the appearance of moderate to severe eczema, a new, preliminary trial finds.

Scientists have uncovered the physiological mechanics underlying inflammation and obesity by tracking the actions of 'guardian immune cells' in response to changes in diet. They believe their work may herald a new era of ...

The natural life cycle of cells that line the intestine is critical to preserving stable conditions in the gut, according to new research led by a Weill Cornell Medicine investigator. The findings may lead to the development ...

As we head into allergy season, you may feel less likely to grab a hanky and sneeze. That's because new University of Florida research shows a probiotic combination might help reduce hay fever symptoms, if it's taken during ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:
Epigenetic enzyme found to be lacking in some patients with Crohn's disease - Medical Xpress